Compare Stocks

Date Range: 

 Heron TherapeuticsSupernus PharmaceuticalsADC TherapeuticsAurinia PharmaceuticalsAmneal Pharmaceuticals
SymbolNASDAQ:HRTXNASDAQ:SUPNNYSE:ADCTNASDAQ:AUPHNYSE:AMRX
Price Information
Current Price$17.56$29.35$22.48$10.00$5.31
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.71.91.71.52.0
Analysis Score3.43.53.43.43.4
Community Score2.73.03.73.02.2
Dividend Score0.00.00.00.00.0
Ownership Score1.71.70.80.80.0
Earnings & Valuation Score0.61.30.60.04.4
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$26.00$37.50$49.25$28.00$7.00
% Upside from Price Target48.06% upside27.77% upside119.08% upside180.00% upside31.83% upside
Trade Information
Market Cap$1.61 billion$1.56 billion$1.55 billion$1.28 billion$1.59 billion
Beta1.521.38N/A0.871.27
Average Volume1,034,451579,335328,1564,369,1251,807,015
Sales & Book Value
Annual Revenue$145.97 million$392.76 million$2.34 million$320,000.00$1.63 billion
Price / Sales11.033.96661.834,003.780.98
CashflowN/A$2.60 per shareN/AN/A$1.24 per share
Price / CashN/A11.30N/AN/A4.29
Book Value$4.48 per share$11.35 per shareN/A$2.45 per share$1.16 per share
Price / Book3.922.594.084.58
Profitability
Net Income$-204,750,000.00$113.06 million$-116,480,000.00$-123,850,000.00$-361,920,000.00
EPS($2.50)$2.10($2.36)($0.89)$0.27
Trailing P/E RatioN/A12.18N/AN/A12.95
Forward P/E RatioN/A18.58N/AN/A8.05
P/E GrowthN/AN/AN/AN/A0.29
Net Margins-216.18%27.09%N/A-173,992.23%3.30%
Return on Equity (ROE)-65.06%20.02%N/A-36.98%42.02%
Return on Assets (ROA)-49.14%9.67%N/A-31.06%3.82%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.53%0.28%N/A8.20%
Current Ratio3.60%1.84%15.55%17.23%2.31%
Quick Ratio3.16%1.70%15.55%16.95%1.60%
Ownership Information
Institutional Ownership Percentage99.01%96.11%40.88%51.21%33.49%
Insider Ownership Percentage12.85%6.57%N/AN/A26.32%
Miscellaneous
Employees2235632082946,000
Shares Outstanding91.68 million53.02 million68.89 million128.12 million299.82 million
Next Earnings Date5/12/2021 (Estimated)8/17/2021 (Estimated)8/17/2021 (Estimated)8/10/2021 (Estimated)8/5/2021 (Estimated)
OptionableOptionableOptionableNot OptionableOptionableOptionable
SourceHeadline
Amneal Pharmaceuticals Inc. (NYSE:AMRX): The most interesting shares todayAmneal Pharmaceuticals Inc. (NYSE:AMRX): The most interesting shares today
marketingsentinel.com - May 10 at 3:28 PM
RBC Capital Mkts slashes price target on Amneal Pharmaceuticals Inc. [AMRX] – find out why.RBC Capital Mkts slashes price target on Amneal Pharmaceuticals Inc. [AMRX] – find out why.
dbtnews.com - May 10 at 3:28 PM
Amneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q1 2021 Results - Earnings Call TranscriptAmneal Pharmaceuticals, Inc. (AMRX) CEO Chintu Patel on Q1 2021 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 6:40 PM
Amneal Pharmaceuticals, Inc. (AMRX) Q1 2021 Earnings Call TranscriptAmneal Pharmaceuticals, Inc. (AMRX) Q1 2021 Earnings Call Transcript
fool.com - May 7 at 6:19 PM
Amneal Pharmaceuticals (NYSE:AMRX)  Shares Down 7.4% Amneal Pharmaceuticals (NYSE:AMRX) Shares Down 7.4%
americanbankingnews.com - May 7 at 3:32 PM
Amneal Reports First Quarter 2021 Financial ResultsAmneal Reports First Quarter 2021 Financial Results
uk.finance.yahoo.com - May 7 at 9:44 AM
Amneal: Q1 Earnings SnapshotAmneal: Q1 Earnings Snapshot
sfgate.com - May 7 at 9:44 AM
Amneal Pharmaceuticals (AMRX) Q1 Earnings Beat EstimatesAmneal Pharmaceuticals (AMRX) Q1 Earnings Beat Estimates
finance.yahoo.com - May 7 at 9:44 AM
Amneal Pharmaceuticals (NYSE:AMRX) Stock Rating Upgraded by TheStreetAmneal Pharmaceuticals (NYSE:AMRX) Stock Rating Upgraded by TheStreet
marketbeat.com - May 6 at 7:15 AM
Amneal Pharmaceuticals A earnings preview: what Wall Street is expectingAmneal Pharmaceuticals A earnings preview: what Wall Street is expecting
markets.businessinsider.com - May 5 at 10:36 PM
5.26% jump drives Amneal Pharmaceuticals Inc. (AMRX) into becoming a top stock for investors5.26% jump drives Amneal Pharmaceuticals Inc. (AMRX) into becoming a top stock for investors
marketingsentinel.com - May 4 at 10:36 AM
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Short Interest Up 29.4% in AprilAmneal Pharmaceuticals, Inc. (NYSE:AMRX) Short Interest Up 29.4% in April
americanbankingnews.com - May 3 at 7:18 AM
Earnings Preview: Amneal Pharmaceuticals (AMRX) Q1 Earnings Expected to DeclineEarnings Preview: Amneal Pharmaceuticals (AMRX) Q1 Earnings Expected to Decline
finance.yahoo.com - April 30 at 5:51 PM
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Surged 7.98% In 6 Months – Here’s What Happens NextAmneal Pharmaceuticals, Inc. (NYSE:AMRX) Surged 7.98% In 6 Months – Here’s What Happens Next
marketingsentinel.com - April 24 at 1:40 PM
What do Wall Street analysts think about Amneal Pharmaceuticals, Inc. (NYSE:AMRX) stock?What do Wall Street analysts think about Amneal Pharmaceuticals, Inc. (NYSE:AMRX) stock?
stocksregister.com - April 18 at 9:26 AM
Amneal to Report First Quarter 2021 Results on May 7, 2021Amneal to Report First Quarter 2021 Results on May 7, 2021
finance.yahoo.com - April 15 at 8:31 AM
Is Now The Right Time To Buy Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Stock?Is Now The Right Time To Buy Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Stock?
stocksregister.com - April 13 at 9:06 AM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Amneal Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of DirectorsSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Amneal Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - April 12 at 8:53 AM
Is Amneal Pharmaceuticals, Inc.s (NYSE:AMRX) 19% ROE Strong Compared To Its Industry?Is Amneal Pharmaceuticals, Inc.'s (NYSE:AMRX) 19% ROE Strong Compared To Its Industry?
finance.yahoo.com - April 9 at 7:25 AM
Amneal Pharmaceuticals (NYSE:AMRX) Shareholders Have Enjoyed An Impressive 121% Share Price GainAmneal Pharmaceuticals (NYSE:AMRX) Shareholders Have Enjoyed An Impressive 121% Share Price Gain
nasdaq.com - April 7 at 9:18 AM
Amneal Pharma buys Kashiv Specialty PharmaAmneal Pharma buys Kashiv Specialty Pharma
medicaldialogues.in - April 6 at 8:32 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Amneal Pharmaceuticals, Inc. (AMRX)SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Amneal Pharmaceuticals, Inc. (AMRX)
finance.yahoo.com - March 31 at 2:48 PM
If You’re Not Bullish on Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Now, You’ll Kick Yourself LaterIf You’re Not Bullish on Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Now, You’ll Kick Yourself Later
stocksregister.com - March 29 at 10:09 AM
Amneal Posts Better-Than-Expected Q4 Results; Upbeat 2021 Revenue OutlookAmneal Posts Better-Than-Expected Q4 Results; Upbeat 2021 Revenue Outlook
finance.yahoo.com - March 1 at 1:29 PM
Analysts Have Conflicting Sentiments on These Healthcare Companies: BridgeBio Pharma (BBIO), Amneal Pharmaceuticals (AMRX) and VBI Vaccines (VBIV)Analysts Have Conflicting Sentiments on These Healthcare Companies: BridgeBio Pharma (BBIO), Amneal Pharmaceuticals (AMRX) and VBI Vaccines (VBIV)
smarteranalyst.com - February 26 at 10:44 PM
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2020 Earnings Call TranscriptAmneal Pharmaceuticals, Inc. (AMRX) Q4 2020 Earnings Call Transcript
fool.com - February 26 at 6:35 PM
DateCompanyBrokerageAction
12/2/2020Heron TherapeuticsSVB LeerinkBoost Price Target
9/8/2020Heron TherapeuticsStifel NicolausReiterated Rating
8/6/2020Heron TherapeuticsNorthland SecuritiesInitiated Coverage
5/26/2020Heron TherapeuticsGuggenheimInitiated Coverage
5/18/2020Heron TherapeuticsFIXInitiated Coverage
4/15/2020Heron TherapeuticsNeedham & Company LLCReiterated Rating
2/20/2020Heron TherapeuticsCantor FitzgeraldReiterated Rating
1/15/2020Heron TherapeuticsCowenReiterated Rating
10/3/2019Heron TherapeuticsJMP SecuritiesLower Price Target
8/13/2019Heron TherapeuticsEvercore ISIReiterated Rating
4/19/2021Supernus PharmaceuticalsJefferies Financial GroupUpgrade
2/3/2021Supernus PharmaceuticalsPiper SandlerBoost Price Target
11/8/2019Supernus PharmaceuticalsBerenberg BankDowngrade
8/7/2019Supernus PharmaceuticalsMizuhoReiterated Rating
3/4/2019Supernus PharmaceuticalsB. RileySet Price Target
1/16/2019Supernus PharmaceuticalsPiper Jaffray CompaniesSet Price Target
5/10/2021ADC TherapeuticsMorgan StanleyLower Price Target
5/3/2021ADC TherapeuticsHC WainwrightBoost Price Target
6/9/2020ADC TherapeuticsBank of AmericaInitiated Coverage
5/7/2021Aurinia PharmaceuticalsRoyal Bank of CanadaLower Price Target
5/7/2021Aurinia PharmaceuticalsOppenheimerReiterated Rating
11/3/2020Aurinia PharmaceuticalsBloom BurtonDowngrade
6/16/2020Aurinia PharmaceuticalsBTIG ResearchInitiated Coverage
3/15/2021Amneal PharmaceuticalsThe Goldman Sachs GroupUpgrade
3/1/2021Amneal PharmaceuticalsBarclaysBoost Price Target
5/13/2020Amneal PharmaceuticalsSunTrust BanksBoost Price Target
12/12/2019Amneal PharmaceuticalsRaymond JamesDowngrade
11/12/2019Amneal PharmaceuticalsJPMorgan Chase & Co.Downgrade
8/6/2019Amneal PharmaceuticalsBMO Capital MarketsLower Price Target
(Data available from 5/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.